BeiGene, Ltd. NASDAQ:BGNE

Founder-led company

BeiGene, Ltd. stock price today

$184.71
+2.82
+1.55%
Financial Health
0
1
2
3
4
5
6
7
8
9

BeiGene, Ltd. stock price monthly change

+19.53%
month

BeiGene, Ltd. stock price quarterly change

+19.53%
quarter

BeiGene, Ltd. stock price yearly change

+1.65%
year

BeiGene, Ltd. key metrics

Market Cap
19.85B
Enterprise value
22.87B
P/E
-13.22
EV/Sales
16.15
EV/EBITDA
-12.41
Price/Sales
18.46
Price/Book
5.96
PEG ratio
0.48
EPS
-6.96
Revenue
2.76B
EBITDA
-1.05B
Income
-784.42M
Revenue Q/Q
67.85%
Revenue Y/Y
77.42%
Profit margin
-141.86%
Oper. margin
-126.4%
Gross margin
-36.09%
EBIT margin
-126.4%
EBITDA margin
-38.07%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

BeiGene, Ltd. stock price history

BeiGene, Ltd. stock forecast

BeiGene, Ltd. financial statements

Average Price Target
Last Year

$267.33

Potential upside: 44.73%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

BeiGene, Ltd. (NASDAQ:BGNE): Profit margin
Jun 2023 595.26M -381.13M -64.03%
Sep 2023 781.30M 215.41M 27.57%
Dec 2023 634.40M -367.55M -57.94%
Mar 2024 751.65M -251.15M -33.41%
BeiGene, Ltd. (NASDAQ:BGNE): Earnings per share (EPS)
2022-11-09 -5.39 -5.39
2022-12-31 -2.35967 -4.29186
2023-02-28 -4.42213 -4.29
BeiGene, Ltd. (NASDAQ:BGNE): Debt to assets
Jun 2023 5728736000 1.93B 33.69%
Sep 2023 5524879000 1.76B 31.89%
Dec 2023 5805275000 2.23B 38.48%
Mar 2024 5667681000 2.27B 40.13%
BeiGene, Ltd. (NASDAQ:BGNE): Cash Flow
Jun 2023 -293.88M 67.8M 166.08M
Sep 2023 -78.15M -186.27M -76.78M
Dec 2023 -221.63M -62.58M 347.04M
Mar 2024 -308.57M -209.83M 162.29M

BeiGene, Ltd. alternative data

BeiGene, Ltd. (NASDAQ:BGNE): Employee count
Aug 2023 9,400
Sep 2023 10,000
Oct 2023 10,000
Nov 2023 10,000
Dec 2023 10,000
Jan 2024 10,000
Feb 2024 10,000
Mar 2024 10,600
Apr 2024 10,600
May 2024 10,600
Jun 2024 10,000
Jul 2024 10,000

BeiGene, Ltd. other data

1.04% -2.63%
of BGNE is owned by hedge funds
13.95M -35.42M
shares is hold by hedge funds

BeiGene, Ltd. (NASDAQ:BGNE): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 397
Mar 2024 0 50000
Apr 2024 0 50000
Jun 2024 0 14442
Jul 2024 0 1306
Sep 2024 0 16895
Oct 2024 0 15279
Nov 2024 0 48351
Dec 2024 0 18921277
Transaction Date Insider Security Shares Price per share Total value Source
Option
OYLER JOHN director, officer.. Share Option (Right to Buy) 1,300,000 $0.5 $650,000
Option
OYLER JOHN director, officer.. Ordinary Shares 1,300,000 $0.5 $650,000
Sale
WANG XIAODONG director, other: .. American Depositary Shares 1,300 $188.79 $245,428
Sale
WANG XIAODONG director, other: .. American Depositary Shares 1,833 $190.57 $349,311
Sale
WANG XIAODONG director, other: .. American Depositary Shares 993 $191.78 $190,435
Sale
WANG XIAODONG director, other: .. American Depositary Shares 1,374 $192.61 $264,642
Sale
WANG XIAODONG director, other: .. American Depositary Shares 725 $194.01 $140,655
Sale
WANG XIAODONG director, other: .. American Depositary Shares 300 $195.67 $58,700
Option
WANG XIAODONG director, other: .. American Depositary Shares 41,760 $6.5 $271,440
Sale
WANG XIAODONG director, other: .. American Depositary Shares 2,600 $183.6 $477,368
Patent
Application
Filling date: 24 Jul 2020 Issue date: 8 Sep 2022
Application
Filling date: 17 Jul 2020 Issue date: 25 Aug 2022
Application
Filling date: 3 Jul 2020 Issue date: 25 Aug 2022
Application
Filling date: 24 Jul 2020 Issue date: 11 Aug 2022
Application
Filling date: 29 May 2020 Issue date: 28 Jul 2022
Application
Filling date: 21 May 2020 Issue date: 21 Jul 2022
Grant
Filling date: 13 Jul 2021 Issue date: 19 Jul 2022
Grant
Filling date: 12 Aug 2018 Issue date: 5 Jul 2022
Application
Filling date: 24 Nov 2021 Issue date: 19 May 2022
Application
Filling date: 15 Nov 2021 Issue date: 5 May 2022
Friday, 27 December 2024
businesswire.com
Monday, 23 December 2024
businesswire.com
Thursday, 12 December 2024
businesswire.com
Monday, 9 December 2024
businesswire.com
Wednesday, 4 December 2024
businesswire.com
Monday, 2 December 2024
businesswire.com
Sunday, 1 December 2024
seekingalpha.com
Wednesday, 27 November 2024
businesswire.com
Tuesday, 26 November 2024
businesswire.com
Tuesday, 19 November 2024
prnewswire.com
businesswire.com
Thursday, 14 November 2024
businesswire.com
Tuesday, 12 November 2024
businesswire.com
Wednesday, 6 November 2024
seekingalpha.com
businesswire.com
Tuesday, 5 November 2024
businesswire.com
Monday, 28 October 2024
businesswire.com
Monday, 21 October 2024
businesswire.com
Wednesday, 16 October 2024
businesswire.com
Monday, 7 October 2024
zacks.com
Thursday, 26 September 2024
businesswire.com
businesswire.com
Monday, 9 September 2024
businesswire.com
businesswire.com
Wednesday, 28 August 2024
zacks.com
Monday, 26 August 2024
zacks.com
businesswire.com
Monday, 12 August 2024
zacks.com
Friday, 14 June 2024
businesswire.com
Thursday, 13 June 2024
businesswire.com
  • What's the price of BeiGene, Ltd. stock today?

    One share of BeiGene, Ltd. stock can currently be purchased for approximately $184.71.

  • When is BeiGene, Ltd.'s next earnings date?

    Unfortunately, BeiGene, Ltd.'s (BGNE) next earnings date is currently unknown.

  • Does BeiGene, Ltd. pay dividends?

    No, BeiGene, Ltd. does not pay dividends.

  • How much money does BeiGene, Ltd. make?

    BeiGene, Ltd. has a market capitalization of 19.85B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 73.65% to 2.46B US dollars. BeiGene, Ltd. made a loss 881.71M US dollars in net income (profit) last year or -$4.29 on an earnings per share basis.

  • What is BeiGene, Ltd.'s stock symbol?

    BeiGene, Ltd. is traded on the NASDAQ under the ticker symbol "BGNE".

  • What is BeiGene, Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of BeiGene, Ltd.?

    Shares of BeiGene, Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are BeiGene, Ltd.'s key executives?

    BeiGene, Ltd.'s management team includes the following people:

    • Dr. Xiaodong Wang Ph.D. Co-Founder, Chairman of the Scientific Advisory Board & Non-Executive Director(age: 62, pay: $4,250,000)
    • Mr. John V. Oyler Co-Founder, Executive Chairman & Chief Executive Officer(age: 57, pay: $1,410,000)
    • Dr. Xiaobin Wu Ph.D. Pres, Chief Operating Officer & GM of China(age: 63, pay: $1,230,000)
    • Dr. Edna Huang M.D. Chief Medical Officer of Hematology(age: 52, pay: $749,550)
  • Is BeiGene, Ltd. founder-led company?

    Yes, BeiGene, Ltd. is a company led by its founders Dr. Xiaodong Wang Ph.D. and Mr. John V. Oyler.

  • How many employees does BeiGene, Ltd. have?

    As Jul 2024, BeiGene, Ltd. employs 10,000 workers, which is 6% less then previous quarter.

  • When BeiGene, Ltd. went public?

    BeiGene, Ltd. is publicly traded company for more then 9 years since IPO on 3 Feb 2016.

  • What is BeiGene, Ltd.'s official website?

    The official website for BeiGene, Ltd. is beigene.com.

  • Where are BeiGene, Ltd.'s headquarters?

    BeiGene, Ltd. is headquartered at 55 Cambridge Parkway, Cambridge, MA.

  • How can i contact BeiGene, Ltd.?

    BeiGene, Ltd.'s mailing address is 55 Cambridge Parkway, Cambridge, MA and company can be reached via phone at +7 818011800.

  • What is BeiGene, Ltd. stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for BeiGene, Ltd. in the last 12 months, the avarage price target is $267.33. The average price target represents a 44.73% change from the last price of $184.71.

BeiGene, Ltd. company profile:

BeiGene, Ltd.

beigene.com
Exchange:

NASDAQ

Full time employees:

10,600

Industry:

Biotechnology

Sector:

Healthcare

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

55 Cambridge Parkway
Cambridge, MA 02142

CIK: 0001651308
ISIN: US07725L1026
CUSIP: 07725L102